Tags

Type your tag names separated by a space and hit enter

Recent advances in nonalcholic fatty liver disease.
Curr Opin Gastroenterol. 2008 May; 24(3):320-7.CO

Abstract

PURPOSE OF REVIEW

The purpose of this review is to summarize recent advances in defining the clinical features, pathophysiology, natural history, and treatment of nonalcoholic fatty liver disease.

RECENT FINDINGS

Nonalcoholic fatty liver disease is present in approximately 30% of the US population. A histologic grading and staging system has been developed and validated. Nonalcoholic fatty liver disease increases the risk of developing the metabolic syndrome. The presence and severity of nonalcoholic fatty liver disease correlates with the severity of obesity, fat distribution, age, and presence of other features of the metabolic syndrome. Fifteen to 20% of subjects with nonalcoholic steatohepatitis develop cirrhosis. Hepatic steatosis is associated with an increase in both free fatty acid delivery to the liver for re-esterification and increased de-novo lipogenesis. Several mechanisms of hepatocyte injury and death including free fatty acid toxicity, increased free cholesterol, cytokine-mediated injury and activation of the unfolded protein response have been defined. While many therapeutic targets have been identified and pilot studies performed, a definitive treatment for nonalcoholic steatohepatitis remains to be established.

SUMMARY

Nonalcoholic fatty liver disease is a widely prevalent disease that is critically linked to insulin resistance and the metabolic syndrome. While much new information on the pathogenesis and natural history of nonalcoholic steatohepatitis is available, an effective therapy remains to be established.

Authors+Show Affiliations

Divisoipn of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

18408460

Citation

Greenfield, Victoria, et al. "Recent Advances in Nonalcholic Fatty Liver Disease." Current Opinion in Gastroenterology, vol. 24, no. 3, 2008, pp. 320-7.
Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol. 2008;24(3):320-7.
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008). Recent advances in nonalcholic fatty liver disease. Current Opinion in Gastroenterology, 24(3), 320-7. https://doi.org/10.1097/MOG.0b013e3282fbccf2
Greenfield V, Cheung O, Sanyal AJ. Recent Advances in Nonalcholic Fatty Liver Disease. Curr Opin Gastroenterol. 2008;24(3):320-7. PubMed PMID: 18408460.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent advances in nonalcholic fatty liver disease. AU - Greenfield,Victoria, AU - Cheung,Onpan, AU - Sanyal,Arun J, PY - 2008/4/15/pubmed PY - 2008/6/17/medline PY - 2008/4/15/entrez SP - 320 EP - 7 JF - Current opinion in gastroenterology JO - Curr Opin Gastroenterol VL - 24 IS - 3 N2 - PURPOSE OF REVIEW: The purpose of this review is to summarize recent advances in defining the clinical features, pathophysiology, natural history, and treatment of nonalcoholic fatty liver disease. RECENT FINDINGS: Nonalcoholic fatty liver disease is present in approximately 30% of the US population. A histologic grading and staging system has been developed and validated. Nonalcoholic fatty liver disease increases the risk of developing the metabolic syndrome. The presence and severity of nonalcoholic fatty liver disease correlates with the severity of obesity, fat distribution, age, and presence of other features of the metabolic syndrome. Fifteen to 20% of subjects with nonalcoholic steatohepatitis develop cirrhosis. Hepatic steatosis is associated with an increase in both free fatty acid delivery to the liver for re-esterification and increased de-novo lipogenesis. Several mechanisms of hepatocyte injury and death including free fatty acid toxicity, increased free cholesterol, cytokine-mediated injury and activation of the unfolded protein response have been defined. While many therapeutic targets have been identified and pilot studies performed, a definitive treatment for nonalcoholic steatohepatitis remains to be established. SUMMARY: Nonalcoholic fatty liver disease is a widely prevalent disease that is critically linked to insulin resistance and the metabolic syndrome. While much new information on the pathogenesis and natural history of nonalcoholic steatohepatitis is available, an effective therapy remains to be established. SN - 1531-7056 UR - https://www.unboundmedicine.com/medline/citation/18408460/Recent_advances_in_nonalcholic_fatty_liver_disease_ L2 - https://doi.org/10.1097/MOG.0b013e3282fbccf2 DB - PRIME DP - Unbound Medicine ER -